Coronavirus: an AstraZeneca antibody therapy approved by the Haute Autorité de Santé

Published by Laurent P. · Published on 15 December 2021 at 10h18
This Friday December 10, the Haute Autorité de Santé announced they have approved the use of Evusheld (tixagevimab-cilgavimab), a coronavirus monoclonal antibody-based therapy developed by AstraZeneca. But the therapy includes cardiovascular risks… Here is more on the matter.

A new coronavirus therapy has been approved in France… The Haute Autorité de Santé has announced they have approved the use of Evusheld (tixagevimab-cilgavimab), a monoclonal antibody-based therapy developed by Swedish-British laboratory AstraZeneca.

It has been designed for patients aged 18+ and showing a very high risk of severe infection when not vaccinated or not eligible to vaccination. A therapy given intramuscularly, effective 14 days after the injection and cutting – according to the HAS – down to 80% the number of symptomatic cases, also protecting against the virus for at least six months after the injection. This is a single-dose jab.

But this therapy is not to be recommended for everyone… And for good reason, it shown during the clinical trials an “identified cardiovascular risk”, as reported by our peers from Franceinfo. Evusheld is not recommended for people who have at least two factors likely to lead to cardiovascular risk after injection, according to the Haute Autorité de Santé, such as diabetes, obesity, high blood pressure, tobacco addiction, dyslipidemia and so on.

Please note the Haute Autorité de Santé also stated in a release issued this Friday they are advising against the emergency use of molnupiravir, enabling – when the drug is taken as a prevention – to cut down the risk of severe disease when contaminated.

Practical information

Comments